But certainly, I think long-term, it can be a very, very strong opportunity. A third issue may relate to sotagliflozin, which Viatris opted to license from its developer Lexicon Therapeutics ...

Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, 2025.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Shares of Viatris Inc. VTRS dropped 0.68% to $11.72 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...

As Leo stands in his office, overseeing the entrance of Viatris' bustling office in the Netherlands, he reflects on the 50 years that have shaped his journey with the company. From his early days ...

Shares of Viatris Inc. VTRS shed 0.33% to $11.96 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,918.25 ...